IC Regimen: Delaying Resistance to Lorlatinib in ALK Driven Cancers by Adding Repurposed Itraconazole and Cilostazol

Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer

Watkins, D. N., Berman, D. M., Burkholder, S. G., Wang, B., Beachy, P. A., & Baylin, S. B. (2003) · Nature · doi:10.1038/nature01493 · Cited by 1,082 · see citing works

The role of the Hedgehog signaling pathway in cancer: A comprehensive review

Škoda, A. M., Simovic, D., Karin‐Kujundžić, V., Kardum, V., Vranić, S., & Šerman, L. (2017) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2018.2756 · Cited by 782 · see citing works

Role of platelets and platelet receptors in cancer metastasis

Schlesinger, M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0669-2 · Cited by 698 · see citing works

In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.

Michelson, A. D., Barnard, M. R., Hechtman, H. B., MacGregor, H., Connolly, R. J., Loscalzo, J., & VALERI, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11877 · Cited by 551 · see citing works

Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways

Stecca, B. A., Mas, C., Clement, V., Zbinden, M., Correa‐Rocha, R., Piguet, V., Beermann, F., & Altaba, A. R. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700776104 · Cited by 525 · see citing works

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Cooper, A. J., Sequist, L. V. D., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 525 · see citing works

FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer

Yang, S., Liu, Y., Li, M., Ng, C. S. H., Yang, S., Wang, S., Zou, C., Dong, Y., Du, J., Long, X., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0700-1 · Cited by 415 · see citing works

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Shaw, A. T., Solomon, B., Besse, B., Bauer, T. M., Lin, C., Soo, R. A., Riely, G. J., Ou, S. I., Clancy, J. S., Li, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02236 · Cited by 385 · see citing works

Platelet Physiology

Frelinger, A. L., Michelson, A. D., & Gremmel, T. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1564835 · Cited by 368 · see citing works

Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab

Liu, J., Li, S., Zhang, S., Liu, Y., Ma, L., Zhu, J., Xin, Y., Wang, Y., Yang, C., & Cheng, Y. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22964 · Cited by 364 · see citing works

Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists

Kim, J., Aftab, B. T., Tang, J. Y., Kim, D., Lee, A. H., Rezaee, M., Kim, J., Chen, B., King, E. M., Borodovsky, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.017 · Cited by 346 · see citing works

P-Selectin and Platelet Clearance

Berger, G., Hartwell, D. W., & Wagner, D. D. (1998) · Blood · doi:10.1182/blood.v92.11.4446 · Cited by 302 · see citing works

Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition

Roskoski, R. J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 301 · see citing works

Platelets Facilitate the Wound-Healing Capability of Mesenchymal Stem Cells by Mitochondrial Transfer and Metabolic Reprogramming

Levoux, J., Prola, A., Lafuste, P., Gervais, M., Chevallier, N., Koumaiha, Z., Kefi, K., Braud, L., Schmitt, A., Yacia, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.12.006 · Cited by 297 · see citing works

A crucial requirement for Hedgehog signaling in small cell lung cancer

Park, K.-S., Martelotto, L. G., Peifer, M., Sos, M. L., Karnezis, A. N., Mahjoub, M. R., Bernard, K., Conklin, J. F., Szczepny, A., Yuan, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2473 · Cited by 247 · see citing works

Wnt signaling in lung cancer

Mazières, J., He, B., You, L., Xu, Z., & Jablons, D. M. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.08.040 · Cited by 245 · see citing works

P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis

Chen, M., & Geng, J.-G. (2006) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-006-0010-6 · Cited by 226 · see citing works

The pharmacology of cilostazol

Schrör, K. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.0040s2s14.x · Cited by 213 · see citing works

Applications of the regenerative capacity of platelets in modern medicine

Cecerska‐Heryć, E., Goszka, M., Serwin, N. M., Roszak, M., Grygorcewicz, B., Heryć, R., & Dołęgowska, B. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.11.003 · Cited by 207 · see citing works

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Dagogo‐Jack, I., Yoda, S., Lennerz, J. K., Langenbucher, A., Lin, J. J., Rooney, M. M., Prutisto-Chang, K., Oh, A., Adams, N. A., Yeap, B. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3906 · Cited by 204 · see citing works

Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding

Goto, S. (2005) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2005.09.002 · Cited by 201 · see citing works

Cilostazol (Pletal®): A Dual Inhibitor of Cyclic Nucleotide Phosphodiesterase Type 3 and Adenosine Uptake

Liu, Y., Shakur, Y., Yoshitake, M., & Kambayashi, J. (2001) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2001.tb00076.x · Cited by 200 · see citing works

Clopidogrel but not aspirin reduces P‐selectin expression and formation of platelet‐leukocyte aggregates in patients with atherosclerotic vascular disease*

Klinkhardt, U., Bauersachs, R. M., Adams, J., Graff, J., Lindhoff‐Last, E., & Harder, S. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.13 · Cited by 193 · see citing works

ALK-positive lung cancer: a moving target

Schneider, J. L., Lin, J. J., & Shaw, A. T. (2023) · Nature Cancer · doi:10.1038/s43018-023-00515-0 · Cited by 190 · see citing works

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

Antonarakis, E. S., Heath, E. I., Smith, D. C., Rathkopf, D., Blackford, A. L., Danila, D. C., King, S., Frost, A., Ajiboye, A. S., Zhao, M., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-314 · Cited by 180 · see citing works

Mechanistic explanation for platelet contribution to cancer metastasis

Stegner, D., Dütting, S., & Nieswandt, B. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50025-4 · Cited by 179 · see citing works

CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways

Huang, C., Fong, Y., Lee, C., Chen, M., Tsai, H., Hsu, H., & Tang, C. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.014 · Cited by 177 · see citing works

Cilostazol as a Unique Antithrombotic Agent

Kambayashi, J., Liu, Y., Sun, B., Shakur, Y., Yoshitake, M., & Czerwiec, F. S. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453910 · Cited by 172 · see citing works

Clinical Management of Adverse Events Associated with Lorlatinib

Bauer, T. M., Felip, E., Solomon, B., Thurm, H. C., Peltz, G., Chioda, M. D., & Shaw, A. T. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0380 · Cited by 171 · see citing works

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer

Brechbiel, J. L., Miller, K. M., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.003 · Cited by 167 · see citing works

Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived Galectin-3

Mammadova‐Bach, E., Gil‐Pulido, J., Sarukhanyan, E., Burkard, P., Shityakov, S., Schonhart, C., Stegner, D., Remer, K. A., Nurden, P., Nurden, A. T., et al. (2020) · Blood · doi:10.1182/blood.2019002649 · Cited by 165 · see citing works

Platelet–Cancer Interactions

Stakiw, J., Radosevic, M., Burnouf, T. P. R., & Goubran, H. A. (2014) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0034-1370767 · Cited by 163 · see citing works

The platelet–cancer loop

Goubran, H. A., Burnouf, T. P. R., Radosevic, M., & Ekiaby, M. E. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.01.017 · Cited by 159 · see citing works

ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma

Singh, R. R., Kunkalla, K., Qu, C., Schlette, E. J., Neelapu, S. S., Samaniego, F., & Vega, F. (2011) · Oncogene · doi:10.1038/onc.2011.195 · Cited by 155 · see citing works

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Rudin, C. M., Brahmer, J. R., Juergens, R. A., Hann, C. L., Ettinger, D. S., Sebree, R., Smith, R. D., Aftab, B. T., Huang, P., & Liu, J. O. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c3950 · Cited by 145 · see citing works

Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets

Werther, K., Christensen, I. J., & Nielsen, H. J. (2002) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510260296492 · Cited by 145 · see citing works

LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway

He, Y., Jiang, X., Duan, L., Xiong, Q., Yuan, Y., Liu, P., Jiang, L., Shen, Q., Zhao, S., Yang, C., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01469-6 · Cited by 140 · see citing works

ALKFusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy

Ross, J. S., Ali, S. M., Fasan, O. O., Block, J. G., Pal, S. K., Elvin, J. A., Schrock, A. B., Suh, J. H., Nozad, S., Kim, S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0488 · Cited by 131 · see citing works

Lung cancer stem cells—Origin, characteristics and therapy

Prabavathy, D., Swarnalatha, Y., & Ramadoss, N. (2018) · Stem Cell Investigation · doi:10.21037/sci.2018.02.01 · Cited by 125 · see citing works

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells

Schönherr, C., Ruuth, K., Kamaraj, S., Wang, C.-L., Yang, H.-L., Combaret, V., Djos, A., Martinsson, T., Christensen, J. G., Palmer, R. H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.12 · Cited by 122 · see citing works

Platelet-Leukocyte Interplay in Cancer Development and Progression

Stoiber, D., & Assinger, A. (2020) · Cells · doi:10.3390/cells9040855 · Cited by 119 · see citing works

Analysis of the cilostazol safety database

Pratt, C. M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01719-2 · Cited by 113 · see citing works

Mitochondrial transfer in tunneling nanotubes—a new target for cancer therapy

Guan, F., Wu, X., Zhou, J., Lin, Y., He, Y., Fan, C., Zeng, Z., & Xiong, W. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03069-w · Cited by 111 · see citing works

Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells

Head, S. A., Shi, W., Zhao, L., Gorshkov, K., Pasunooti, K., Chen, Y., Deng, Z., Li, R.-J., Shim, J. S., Tan, W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512867112 · Cited by 111 · see citing works

ALK fusions in the pan-cancer setting: another tumor-agnostic target?

Shreenivas, A. V., Jankú, F., Gouda, M. A., Chen, H., George, B., Kato, S., & Kurzrock, R. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00449-x · Cited by 109 · see citing works

Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP

Lempers, V. J. C., van den Heuvel, J. J. M. W., Rüssel, F. G. M., Aarnoutse, R. E., Burger, D. M., Brüggemann, R. J. M., & Koenderink, J. B. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02931-15 · Cited by 108 · see citing works

Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death

Wang, X., Wei, S., Zhao, Y., Shi, C., Liu, P., Zhang, C., Lei, Y., Zhang, B., Bai, B., Huang, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.034 · Cited by 108 · see citing works

Repurposing itraconazole as an anticancer agent

Tsubamoto, H., Ueda, T., Inoue, K., Sakata, K., Shibahara, H., & Sonoda, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.6325 · Cited by 107 · see citing works

Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways

Wang, W., Dong, X., Liu, Y., Ni, B., Sai, N., You, L., Sun, M., Yao, Y., Qu, C., Yin, X., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110661 · Cited by 105 · see citing works

Effect of Cilostazol on Soluble Adhesion Molecules and Platelet-derived Microparticles in Patients with Diabetes

Shouzu, A., Omoto, S., Hayakawa, T., Kagawa, H., Nishikawa, M., Inada, M., Fujimura, Y., Ikeda, Y., Fukuhara, S., & Nomura, S. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615217 · Cited by 102 · see citing works

The critical role of platelet in cancer progression and metastasis

Zhou, L., Zhang, Z., Tian, Y., Li, Z., Liu, Z., & Zhu, S. (2023) · European journal of medical research · doi:10.1186/s40001-023-01342-w · Cited by 100 · see citing works

P-selectin Cell Adhesion Molecule in Inflammation, Thrombosis, Cancer Growth and Metastasis

Geng, J.-G., Chen, M., & Chou, K. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364720 · Cited by 95 · see citing works

Sonic Hedgehog Signaling Pathway Is Activated in ALK-Positive Anaplastic Large Cell Lymphoma

Singh, R. R., Cho‐Vega, J. H., Davuluri, Y., Ma, S., Kasbidi, F., Milito, C. B., Lennon, P. A., Drakos, E., Medeiros, L. J., Luthra, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1808 · Cited by 94 · see citing works

Itraconazole

Piérard, G. E., Arrese, J. E., & Piérard-Franchimont, C. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.2.287 · Cited by 92 · see citing works

Cilostazol: a Review of Basic Mechanisms and Clinical Uses

Kherallah, R. Y., Khawaja, M., Olson, M., Angiolillo, D. J., & Birnbaum, Y. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07187-x · Cited by 91 · see citing works

Cilostazol for Secondary Prevention of Stroke and Cognitive Decline

McHutchison, C. A., Blair, G. W., Appleton, J. P., Chappell, F. M., Doubal, F., Bath, P. M., & Wardlaw, J. M. (2020) · Stroke · doi:10.1161/strokeaha.120.029454 · Cited by 91 · see citing works

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma

Hasan, M. K., Nafady, A., Takatori, A., Kishida, S., Ohira, M., Suenaga, Y., Hossain, S., Akter, J., Ogura, A., Nakamura, Y., et al. (2013) · Scientific Reports · doi:10.1038/srep03450 · Cited by 90 · see citing works

Human Cancer and Platelet Interaction, a Potential Therapeutic Target

Wang, S., Li, Z., & Xu, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041246 · Cited by 88 · see citing works

Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)

Gupta, A., Unadkat, J. D., & Mao, Q. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20963 · Cited by 87 · see citing works

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces

Huang, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113448 · Cited by 87 · see citing works

The Influence of Platelets on the Promotion of Invasion by Tumor Cells and Inhibition by Antiplatelet Agents

Suzuki, K., Aiura, K., Ueda, M., & Kitajima, M. (2004) · Pancreas · doi:10.1097/00006676-200408000-00008 · Cited by 86 · see citing works

Aberrant Activation of the Hedgehog Signaling Pathway in Malignant Hematological Neoplasms

Ok, C. Y., Singh, R. R., & Vega, F. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.009 · Cited by 83 · see citing works

Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma

Gutzmer, R., & Solomon, J. A. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00648-2 · Cited by 83 · see citing works

Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis

Head, S. A., Shi, W. Q., Yang, E. J., Nacev, B. A., Hong, S. Y., Pasunooti, K. K., Li, R.-J., Shim, J. S., & Liu, J. O. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b00849 · Cited by 82 · see citing works

Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production

Omi, H., Okayama, N., Shimizu, M., Fukutomi, T., Nakamura, A., Imaeda, K., Okouchi, M., & Itoh, M. (2004) · Microvascular Research · doi:10.1016/j.mvr.2004.05.002 · Cited by 80 · see citing works

Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis

Zhang, H., Gao, L., Zhang, B., Zhang, L., & Wang, C. (2016) · Scientific Reports · doi:10.1038/srep22618 · Cited by 80 · see citing works

Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways

Liang, G., Liu, M., Wang, Q., Shen, Y., Mei, H., Li, D., & Liu, W. (2017) · Oncotarget · doi:10.18632/oncotarget.15324 · Cited by 78 · see citing works

Irradiation induces cancer lung metastasis through activation of the cGAS–STING–CCL5 pathway in mesenchymal stromal cells

Zheng, Z., Jia, S., Shao, C., & Shi, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2546-5 · Cited by 78 · see citing works

Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?

Rovida, E., & Stecca, B. A. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.003 · Cited by 77 · see citing works

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3

Halatsch, M.-E., Kast, R. E., Karpel-Massler, G., Mayer, B., Zolk, O., Schmitz, B., Scheuerle, A., Maier, L., Bullinger, L., Mayer-Steinacker, R., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab075 · Cited by 74 · see citing works

Cilostazol

Sorkin, E. M., & Markham, A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914010-00005 · Cited by 74 · see citing works

The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors

Liu, N., Mao, J., Tao, P., Chi, H., Jia, W., & Dong, C. (2022) · Medicine · doi:10.1097/md.0000000000028617 · Cited by 70 · see citing works

Mechanism for the activation of the anaplastic lymphoma kinase receptor

Reshetnyak, A. V., Rossi, P., Myasnikov, A. G., Sowaileh, M. F., Mohanty, J., Nourse, A., Miller, D. J., Lax, I., Schlessinger, J., & Kalodimos, C. G. (2021) · Nature · doi:10.1038/s41586-021-04140-8 · Cited by 70 · see citing works

Cancer cells reprogram to metastatic state through the acquisition of platelet mitochondria

Zhang, W., Zhou, H., Li, H., Mou, H., Yinwang, E., Xue, Y., Wang, S., Zhang, Y., Wang, Z., Chen, T., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113147 · Cited by 68 · see citing works

Platelets, Selectins, and the Control of Tumor Metastasis

Coupland, L. A., & Parish, C. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.04.003 · Cited by 66 · see citing works

Comparison of the Effects of Acetylsalicylic Acid, Ticlopidine and Cilostazol on Primary Hemostasis Using a Quantitative Bleeding Time Test Apparatus

Tamai, Y., Takami, H., Nakahata, R., Ono, F., & Munakata, A. (1999) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000022512 · Cited by 64 · see citing works

The Role of Platelet Cell Surface P-Selectin for the Direct Platelet-Tumor Cell Contact During Metastasis Formation in Human Tumors

Fabricius, H.-Å., Starzonek, S., & Lange, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642761 · Cited by 64 · see citing works

Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells

Hu, Q., Hou, Y.-C., Huang, J., Fang, J.-Y., & Xiong, H. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0526-0 · Cited by 63 · see citing works

Platelet cancer cell interplay as a new therapeutic target

Morris, K., Schnoor, B., & Papa, A. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188770 · Cited by 63 · see citing works

CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development

Melese, E. S., Franks, E., Cederberg, R. A., Harbourne, B., Shi, R., Wadsworth, B. J., Collier, J. L., Halvorsen, E. C., Johnson, F. D., Luu, J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2010905 · Cited by 62 · see citing works

The vascular effects of cilostazol

Weintraub, W. S. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70987-4 · Cited by 62 · see citing works

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells

Bergaggio, E., Tai, W., Aroldi, A., Mecca, C., Landoni, E., Nüesch, M., Mota, I. A., Metović, J., Molinaro, L., Ma, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.004 · Cited by 60 · see citing works

Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies

Aberger, F., Kern, D., Greil, R., & Hartmann, T. N. (2012) · Vitamins and hormones · doi:10.1016/b978-0-12-394622-5.00002-x · Cited by 60 · see citing works

Inhibition of Platelet Aggregation and the Release of P-Selectin from Platelets by Cilostazol

Kariyazono, H., Nakamura, K., Shinkawa, T., Yamaguchi, T., Sakata, R., & Yamada, K. (2001) · Thrombosis Research · doi:10.1016/s0049-3848(00)00415-1 · Cited by 59 · see citing works

Wnt signaling as potential therapeutic target in lung cancer

Yang, J., Chen, J., He, J., Li, J., Shi, J., Cho, W. C. S., & Liu, X. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1154945 · Cited by 58 · see citing works

EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer

Xia, L., Zhu, X., Zhang, L., Xu, Y., Chen, G., & Luo, J. (2019) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1875 · Cited by 55 · see citing works

Action of Platelet-Rich Plasma on In Vitro Cellular Bioactivity: More than Platelets

Beitia, M., Delgado, D., Mercader-Ruiz, J., Sánchez, P., de Dicastillo, L. L., & Sánchez, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065367 · Cited by 54 · see citing works

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh

Neal, J. W., & Sequist, L. V. D. (2010) · Current Treatment Options in Oncology · doi:10.1007/s11864-010-0120-6 · Cited by 53 · see citing works

Platelet Physiology

Gremmel, T., Frelinger, A. L., & Michelson, A. D. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1786387 · Cited by 53 · see citing works

Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2

Uchiyama, S., Shinohara, Y., Katayama, Y., Yamaguchi, T., Handa, S., Matsuoka, K., Ohashi, Y., Tanahashi, N., Yamamoto, H., Genka, C., et al. (2014) · Cerebrovascular Diseases · doi:10.1159/000360811 · Cited by 51 · see citing works

Whole Blood Analysis of Leukocyte‐Platelet Aggregates

Gerrits, A. J., Frelinger, A. L., & Michelson, A. D. (2016) · Current Protocols in Cytometry · doi:10.1002/cpcy.8 · Cited by 50 · see citing works

Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease

Vaidyula, V. R., Bagga, S., Jalagadugula, G. S., Gaughan, J. P., Wilhite, D. B., Comerota, A. J., & Rao, A. K. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-08-0451 · Cited by 44 · see citing works

P‐glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450‐3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib

Li, W., Sparidans, R. W., Wang, Y., Lebre, M. C., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2018) · International Journal of Cancer · doi:10.1002/ijc.31582 · Cited by 44 · see citing works

Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer.

Tsubamoto, H., Sonoda, T., Yamasaki, M., & Inoue, K. (2014) · PubMed · Cited by 43 · see citing works

Platelet-derived mitochondria transfer facilitates wound-closure by modulating ROS levels in dermal fibroblasts

Kim, S., Kim, Y., Yu, S.-H., Lee, S.-E., Park, J.-H., Cho, G., Choi, C. W., Han, K., Kim, C., & Kang, Y. C. (2022) · Platelets · doi:10.1080/09537104.2022.2151996 · Cited by 42 · see citing works

Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions

Wenzel, J., Zeisig, R., & Fichtner, I. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9299-y · Cited by 40 · see citing works

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

Poei, D., Ali, S., Ye, S., & Hsu, R. C. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.25 · Cited by 37 · see citing works

Antiplatelet Therapy as a Risk Factor for Microbleeds in Intracerebral Hemorrhage Patients: Analysis Using Specific Antiplatelet Agents

Naka, H., Nomura, E., Kitamura, J., Imamura, E., Wakabayashi, S., & Matsumoto, M. (2012) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2012.06.001 · Cited by 37 · see citing works

Effect of cilostazol on the progression of carotid intima-media thickness: A meta-analysis of randomized controlled trials

Geng, D.-F., Deng, J., Jin, D., Wu, W., & Wang, J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.09.048 · Cited by 36 · see citing works

Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility

Murata, K., Kameyama, M., Fukui, F., Ohigashi, H., Hiratsuka, M., Sasaki, Y., Kabuto, T., Mukai, M., Mammoto, T., Akedo, H., et al. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006626529536 · Cited by 36 · see citing works

Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer

Chen, C., Breslin, M. B., & Lan, M. S. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.02.014 · Cited by 34 · see citing works

The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis

Sohn, M., & Lim, S. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052593 · Cited by 34 · see citing works

High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score

Rubio, V. E. C., Segura, P. P., Martín, A. J. M., López-Farré, A. J., Ruiz, L. C., & Lorente, J. A. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.09.021 · Cited by 34 · see citing works

Tumor-educated platelets

Najafi, S., Asemani, Y., Majidpoor, J., Mahmoudi, R., Zarch, S. M. A., & Mortezaee, K. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117690 · Cited by 33 · see citing works

Mitochondria Transfer by Platelet-Derived Microparticles Regulates Breast Cancer Bioenergetic States and Malignant Features

Veilleux, V., Pichaud, N., Boudreau, L. H., & Robichaud, G. A. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0329 · Cited by 33 · see citing works

The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells

Foss, A., Muñoz‐Sagredo, L., Sleeman, J. P., & Thiele, W. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-10009-y · Cited by 33 · see citing works

Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival

Andersen, B. L., Myers, J. A., Blevins, T. R., Park, K. R., Smith, R. M., Reisinger, S. A., Carbone, D. P., Presley, C. J., Shields, P. G., & Carson, W. E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282206 · Cited by 31 · see citing works

Gene signature of circulating platelet‐bound neutrophils is associated with poor prognosis in cancer patients

Lecot, P., Ardin, M., Dussurgey, S., Alcazer, V., Moudombi, L., Pereira-Abrantes, M., Hubert, M., Swalduz, A., Hernández‐Vargas, H., Viari, A., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33991 · Cited by 30 · see citing works

Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications

Manolis, A. S., Manolis, T. A., Melita, H., Mikhailidis, D. P., & Manolis, A. S. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1988 · Cited by 29 · see citing works

Impact of platelet-derived mitochondria transfer in the metabolic profiling and progression of metastatic MDA-MB-231 human triple-negative breast cancer cells

Cereceda, L., Cárdenas, C., Khoury, M., Silva-Pavez, E., & Hidalgo, Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1324158 · Cited by 29 · see citing works

Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer

Hao, N., Shen, W., Du, R., Jiang, S., Zhu, J., Chen, Y., Huang, C., Shi, Y., Xiang, R., & Luo, Y. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1233 · Cited by 29 · see citing works

Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma

Shi, M., Zhao, W., Zhou, F., Chen, H., Tang, L., Su, B., & Zhang, J. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.17 · Cited by 28 · see citing works

Targeting phosphodiesterase 3 B enhances cisplatin sensitivity in human cancer cells

Uzawa, K., Kasamatsu, A., Baba, T., Usukura, K., Saito, Y., Sakuma, K., Iyoda, M., Sakamoto, Y., Ogawara, K., Shiiba, M., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.56 · Cited by 28 · see citing works

Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study

Lee, M., Hong, H., Kim, W. K., Zhang, L., Friedlander, T. W., Fong, L. H., Lin, A., Small, E. J., Wei, X. X., Rodvelt, T. J., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.09.013 · Cited by 28 · see citing works

Itraconazole-mediated inhibition of calcium entry into platelet-activating factor-stimulated human neutrophils is due to interference with production of leukotriene B4

Steel, H. C., Tintinger, G. R., Theron, A. J., & Anderson, R. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03470.x · Cited by 28 · see citing works

Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non–Small Cell Lung Cancer

Gerber, D. E., Putnam, W. C., Fattah, F. J., Kernstine, K. H., Brekken, R. A., Pedrosa, I., Skelton, R., Saltarski, J. M., Lenkinski, R. E., Leff, R. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1916 · Cited by 27 · see citing works

The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants

Patel, M. R., Chen, J., McGrory, S. B., O’Gorman, M. T., Nepal, S., Ginman, K., & Pithavala, Y. K. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00872-7 · Cited by 26 · see citing works

In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma

Halatsch, M.-E., Dwucet, A., Schmidt, C. J., Mühlnickel, J., Heiland, T., Zeiler, K., Siegelin, M. D., Kast, R. E., & Karpel-Massler, G. (2021) · Pharmaceuticals · doi:10.3390/ph14121241 · Cited by 26 · see citing works

Itraconazole Modulates Hedgehog, WNT/β-catenin, as well as Akt Signalling, and Inhibits Proliferation of Cervical Cancer Cells

Ueda, T., Tsubamoto, H., Inoue, K., Sakata, K., Shibahara, H., & SONODA, T. (2017) · Anticancer Research · doi:10.21873/anticanres.11720 · Cited by 25 · see citing works

Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial

Nishiyama, Y., Kimura, K., Otsuka, T., Toyoda, Ḱ., Uchiyama, S., Hoshino, H., Sakai, N., Okada, Y., Origasa, H., Naritomi, H., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.039900 · Cited by 25 · see citing works

New perspectives for targeting therapy in ALK-positive human cancers

Zhao, S., Li, J., Xia, Q., Liu, K., & Dong, Z. (2023) · Oncogene · doi:10.1038/s41388-023-02712-8 · Cited by 25 · see citing works

Platelet-derived respiratory-competent mitochondria transfer to mesenchymal stem cells to promote wound healing via metabolic reprogramming

Chen, E., Chen, Z., Chen, L., & Hu, X. (2022) · Platelets · doi:10.1080/09537104.2021.1961717 · Cited by 25 · see citing works

The Effects of Cilostazol on Exercise-induced Ischaemia–reperfusion Injury in Patients with Peripheral Arterial Disease

O'Donnell, M. E., Badger, S. A., Sharif, M. A., Makar, R. R., McEneny, J., Young, I. S., Lee, B., & Soong, C. V. (2008) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2008.11.028 · Cited by 24 · see citing works

Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma.

Tsubamoto, H., Sonoda, T., Yamasaki, M., & Inoue, K. (2014) · PubMed · Cited by 24 · see citing works

Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma

Ning, H., Mitsui, H., Wang, C. Q. F., Suárez‐Fariñas, M., Gonzalez, J., Shah, K. R., Chen, J., Coats, I., Felsen, D., Carucci, J. A., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1357 · Cited by 24 · see citing works

Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib

Li, W., Sparidans, R. W., Wang, Y., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.01.016 · Cited by 23 · see citing works

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib

Berger, L.-A., Janning, M., Velthaus, J.-L., Batalla, I. B., Schatz, S., Falk, M., Iglauer, P., Simon, R., Cao, R., Forcato, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2025 · Cited by 23 · see citing works

CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment

Špaks, A., Svirina, D., Spaka, I., Jaunalksne, I., Breiva, D., Tracums, I., & Krievins, D. K. (2016) · Biomarkers · doi:10.3109/1354750x.2016.1172111 · Cited by 22 · see citing works

Progress in the Mechanism and Clinical Application of Cilostazol

Zheng, H., Yang, H. Q., Gong, D., Mai, L., Qiu, X., Chen, L., Su, X., Wei, R., & Zeng, Z. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191122123855 · Cited by 22 · see citing works

The interaction of platelet-related factors with tumor cells promotes tumor metastasis

Xue, J., Deng, J., Qin, H., Yan, S., Zhao, Z., Qin, L., Liu, J., & Wang, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05126-6 · Cited by 22 · see citing works

Itraconazole and clarithromycin inhibit P‐glycoprotein activity in primary human sinonasal epithelial cells

Lam, A. C., Hoang, J. D., Singleton, A., Han, X., & Bleier, B. S. (2015) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21454 · Cited by 22 · see citing works

The effect of itraconazole on the clinical outcomes of patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a randomized controlled study

Mohamed, A. W., Elbassiouny, M., Elkhodary, D. A., Shawki, M. A., & Saad, A. S. (2021) · Medical Oncology · doi:10.1007/s12032-021-01475-0 · Cited by 22 · see citing works

Species-specific differences in the inhibition of 11β-hydroxysteroid dehydrogenase 2 by itraconazole and posaconazole

Inderbinen, S. G., Zogg, M., Kley, M., Smieško, M., & Odermatt, A. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115387 · Cited by 22 · see citing works

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen

Kast, R. E., Alfieri, A., Assi, H. I., Burns, T. C., Elyamany, A. M., González‐Cao, M., Karpel‐Massler, G., Marosi, C., Salacz, M. E., Sardi, I., et al. (2022) · Cancers · doi:10.3390/cancers14102563 · Cited by 21 · see citing works

From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)

Fabbri, L., Federico, A. D., Astore, M., Marchiori, V., Rejtano, A., Seminerio, R., Gelsomino, F., & Giglio, A. D. (2023) · Diagnostics · doi:10.3390/diagnostics14010048 · Cited by 21 · see citing works

Prostate cancer cell-platelet bidirectional signaling promotes calcium mobilization, invasion and apoptotic resistance via distinct receptor-ligand pairs

Garofano, K., Rashid, K., Smith, M., Brantner, C. A., Suwunnakorn, S., Diemert, D. J., Gordon, O. F., Horvath, A., Khan, S., Popratiloff, A. S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29450-x · Cited by 21 · see citing works

Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis

Lin, M., Meschia, J. F., Gopal, N., Barrett, K. M., Ross, O. A., Ertekin‐Taner, N., & Brott, T. G. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.105581 · Cited by 20 · see citing works

Platelet–lymphocyte ratio is an independent prognostic factor in patients with ALK -positive non-small-cell lung cancer

Han, Y., Wang, J., Hong, L., Sun, L., Zhuang, H., Sun, B., Wang, H., Zhang, X., & Ren, X. (2016) · Future Oncology · doi:10.2217/fon-2016-0317 · Cited by 20 · see citing works

Triazoles bind the C-terminal domain of SMO: Illustration by docking and molecular dynamics simulations the binding between SMO and triazoles

Liu, M., Liang, G., Zheng, H., Zheng, N., Ge, H., & Liu, W. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.012 · Cited by 19 · see citing works

Itraconazole inhibits tumor growth via <scp>CEBPB</scp>‐mediated glycolysis in colorectal cancer

Zhang, Y., Li, L., Chu, F., Wu, H., Xiao, X., Ye, J., & Li, K. (2024) · Cancer Science · doi:10.1111/cas.16082 · Cited by 19 · see citing works

Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review

Patel, S., Armbruster, H., Pardo, G., Archambeau, B., Kim, N. H., Jeter, J., Wu, R., Kendra, K. L., Contreras, C. M., Spaccarelli, N., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297531 · Cited by 19 · see citing works

Platelet Contributions to the (Pre)metastatic Tumor Microenvironment

Roweth, H. G. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1776005 · Cited by 18 · see citing works

VEGF concentrations in tumour arteries and veins from patients with rectal cancer

Werther, K., Bülow, S., Hesselfeldt, P., Jespersen, N., Svendsen, M. N., & Nielsen, H. J. (2002) · Apmis · doi:10.1034/j.1600-0463.2002.1100908.x · Cited by 18 · see citing works

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer

Choo, J. R.-E., & Soo, R. A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744438 · Cited by 17 · see citing works

Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer

Kong, P., Yang, X. M., Zhang, Y., Dong, H., Liu, X., Xu, X., Zhang, X., Shi, Y., Hou, M., & Song, B. (2022) · Journal of Oncology · doi:10.1155/2022/2260625 · Cited by 17 · see citing works

Platelet surface P-selectin molecules increased after exposing platelet to a high shear flow.

Goto, S., Ichikawa, N., Lee, M., Goto, M., Sakai, H., Kim, J. J., Yoshida, M., Handa, M., Ikeda, Y., & Handa, S. (2000) · PubMed · Cited by 17 · see citing works

Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice

Ghadi, M., Hosseinimehr, S. J., Amiri, F. T., Mardanshahi, A., & Noaparast, Z. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173892 · Cited by 17 · see citing works

Itraconazole Alters the Stem Cell Characteristics of A549 and NCI-H460 Human Lung Cancer Cells by Suppressing Wnt Signaling

Chen, C., & Zhang, W. J. (2019) · Medical Science Monitor · doi:10.12659/msm.919347 · Cited by 15 · see citing works

Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing

Zhang, C., Wang, Z., Zhuang, R., Guo, X., Feng, Y., Shen, F., Liu, W., Zhang, Y., Tong, H., Sun, W., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s270481 · Cited by 15 · see citing works

Inhibition of Phosphodiesterase 3A by Cilostazol Dampens Proinflammatory Platelet Functions

Coenen, D. M., Heinzmann, A. C. A., Oggero, S., Albers, H. J., Nagy, M., Hagué, P., Kuijpers, M. J. E., Vanderwinden, J., van der Meer, A. D., Perretti, M., et al. (2021) · Cells · doi:10.3390/cells10081998 · Cited by 14 · see citing works

Lorlatinib as a treatment for ALK-positive lung cancer

Baba, K., & Goto, Y. (2022) · Future Oncology · doi:10.2217/fon-2022-0184 · Cited by 14 · see citing works

Cilostazol for Secondary Prevention of Stroke: Should the Guidelines Perhaps Be Extended?

Galyfos, G. C., & Sianou, A. (2017) · Vascular Specialist International · doi:10.5758/vsi.2017.33.3.89 · Cited by 14 · see citing works

ALKAL1 gene silencing prevents colorectal cancer progression via suppressing Sonic Hedgehog (SHH) signaling pathway

Chen, S., Wang, B., Fu, X., Liang, Y., Chai, X., Ye, Z., Li, R., He, Y., Kong, G., Lian, J., et al. (2020) · Journal of Cancer · doi:10.7150/jca.46447 · Cited by 13 · see citing works

Clinical significance of cancer stem cell markers in lung carcinoma

Zhang, L., Shen, L., & Wu, D. (2021) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5498 · Cited by 12 · see citing works

Safety of Lorlatinib in ALK-Positive Non-Small-Cell Lung Cancer and Management of Central Nervous System Adverse Events

Kılıçkap, S., Ak, S., Dursun, O. U., Şendur, M. A. N., Karadurmuş, N., & Demırcı, U. (2023) · Future Oncology · doi:10.2217/fon-2023-0014 · Cited by 12 · see citing works

Context-dependent ciliary regulation of hedgehog pathway repression in tissue morphogenesis

Hwang, S., White, K. A., Somatilaka, B. N., Wang, B., & Mukhopadhyay, S. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1011028 · Cited by 12 · see citing works

Potentiation of imatinib by cilostazol in sensitive and resistant gastrointestinal stromal tumor cell lines involves YAP inhibition

Vandenberghe, P., Delvaux, M., Hagué, P., Erneux, C., & Vanderwinden, J. (2019) · Oncotarget · doi:10.18632/oncotarget.26734 · Cited by 11 · see citing works

Multifaceted Roles of ALK Family Receptors and Augmentor Ligands in Health and Disease: A Comprehensive Review

Katić, L., & Priscan, A. (2023) · Biomolecules · doi:10.3390/biom13101490 · Cited by 11 · see citing works

Inhibition of Gli leads to antitumor growth and enhancement of cisplatin-induced cytotoxicity in large cell neuroendocrine carcinoma of the lung

Ishiwata, T., Iwasawa, S., Ebata, T., Fan, M., Tada, Y., Tatsumi, K., & Takiguchi, Y. (2018) · Oncology Reports · doi:10.3892/or.2018.6183 · Cited by 11 · see citing works

Efficacy and Safety of Cilostazol for Atherosclerosis: A Meta-analysis of Randomized Controlled Trials

Wan, H., Huang, T., Yang, P., Wu, T., Zhang, H., & Wu, Q. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001195 · Cited by 10 · see citing works

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?

Costa, D. B. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1247568 · Cited by 9 · see citing works

The Efficacy and Safety of Cilostazol vs. Aspirin for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis

Chai, E., Chen, J., Li, C., Zhang, X., Fan, Z., Yang, S., Zhao, K., Li, W., Xiao, Z., Zhang, Y., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.814654 · Cited by 9 · see citing works

Cilostazol eliminates radiation-resistant glioblastoma by re-evoking big conductance calcium-activated potassium channel activity.

Liu, C., Wu, C.-L., Yeh, I., Wu, S., Sze, C., & Gean, P. (2021) · PubMed Central · Cited by 8 · see citing works

Concentrations of VEGF and VEGFR1 in Paired Tumor Arteries and Veins in Patients With Rectal Cancer

Svendsen, M. N., Lykke, J., Werther, K., Christensen, I. J., & Nielsen, H. J. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040042707899 · Cited by 8 · see citing works

Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC

Gemelli, M., Albini, A., Catalano, G., Incarbone, M., Cannone, M., Balladore, E., Ricotta, R., & Pelosi, G. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344648 · Cited by 6 · see citing works

Signaling Switching from Hedgehog-GLI to MAPK Signaling Potentially Serves as a Compensatory Mechanism in Melanoma Cell Lines Resistant to GANT-61

Piteša, N., Kurtović, M., Bartoniček, N., Gkotsi, D. S., Čonkaš, J., Petrić, T., Musani, V., Ozretić, P., Galdo, N. A. R., & Sabol, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051353 · Cited by 6 · see citing works

INHIBITION OF EXPERIMENTAL METASTASIS OF HUMAN ADENOCARCINOMA BY CILOSTAZOL, A PLATELET PHOSPHODIESTERASE INHIBITOR

Inufusa, H., ADACHI, T., Nakamura, M., Shindo, K., Yasutomi, M., & KIMURA, Y. (1995) · Oncology Reports · doi:10.3892/or.2.6.1079 · Cited by 4 · see citing works

Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro

Naderbar, L., Pazhang, Y., & Rezaie, J. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23185 · Cited by 3 · see citing works

Erratum: Cilostazol eliminates radiation-resistant glioblastoma by re-evoking big conductance calcium-activated potassium channel activity.

Liu, C., Wu, C.-L., Yeh, I., Wu, S., Sze, C., & Gean, P. (2021) · PubMed Central · Cited by 2 · see citing works

Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study

Akdağ, G., Alan, Ö., Doğan, A., Yildirim, S., Kınıkoğlu, O., Batu, A., Kudu, E., Gecmen, G. G., Işık, D., Sever, Ö. N., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25029 · Cited by 1 · see citing works

Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial

Salgado, M. Á. V., Barco, S. D., Sepúlveda-Sánchez, J. M., Alonso, M. D., Pineda, E., Balañá, C., Martinez‐García, M., & Gironés, R. (2025) · Nature Communications · doi:10.1038/s41467-025-66747-z · Cited by 4 · see citing works

Microbial infection and treatment strategies in cancer patients

Zhu, K., Yuan, Z., Li, J., & Fu, A. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1582382 · Cited by 3 · see citing works

Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights

Marzi, M., Ghasemian, A., Ghanbariasad, A., Nournia, E., & Zarenezhad, E. (2026) · RSC Advances · doi:10.1039/d5ra09799a

Polypharmacy, polypharmacology, and polypharmacotherapy: clarifying definitions and complementary roles in cancer treatment – a narrative review

González‐Fierro, A., Chávez-Blanco, A. D., Domínguez-Gómez, G., Romo‐Pérez, A., Pastrana-Peralta, P., Gutiérrez-Delgado, F., Kast, R. E., Correa‐Basurto, J., Algara, A. L. C., & Dueñas‐González, A. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2682866

IC Regimen: Delaying Resistance to Lorlatinib in ALK Driven Cancers Using Repurposed Itraconazole and CilostazolPreprint

Kast, R. E. (2024) · Preprints.org · doi:10.20944/preprints202406.0779.v1 · Cited by 3 · see citing works

Lorlatinib effective in multiple settings

Sidaway, P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0141-9

Lorlatinib Shows Promise Against Brain Metastases in ALK+ Lung Cancer

Furlow, B. (2017)

Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer

Darsa, H. E., Abdel-Rahman, O. M., & Sangha, R. S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1774552 · Cited by 22 · see citing works

Lorlatinib Is Well Tolerated and Has Activity in ALK+ and ROS1+ NSCLC

(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2017-210